Skip to content
value.today

Nuwellis, Inc.

NUWE
$3 Mmarket cap on Oct 30, 2026+56.5% since Jan 2024
Compare
World rank
#27,355
Revenue
$8 M
For year ending December-2025
Net income
$-18 M
-211.9% margin
SEC filing
Employees
38
As of December 31, 2025
SEC filing

Nuwellis, Inc. in brief

Nuwellis, Inc. is a listed company in the Medical Devices industry, based in Eden Prairie, Minnesota, USA. Its market value was $3 M on 30 October 2026, which makes it the 27,355th largest listed company in the world and the 4,460th largest in the USA on this site. In the year to December 2025 it had sales of $8 M and a net loss of $18 M. It employs about 38 people and Michael Kendrick McCormick is its chief executive. Its largest business segments by sales in 2025 were Fluid Overload (100%). Its shares trade under the symbol NUWE (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Nuwellis, Inc.

Nuwellis is dedicated to advancing cardiorenal care by enabling earlier, safer, and more controlled fluid management for patients. The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems. The Aquadex SmartFlow® system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics.

From the company's annual report filed with the US SEC: read the report

Nuwellis, Inc. timeline

4 events, 2010–2023
  1. 2010
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2017
  4. ✎
    Renamed CHF Solutions, Inc.
    Formerly Sunshine Heart, Inc..
  5. 2021
  6. ✎
    Renamed Nuwellis, Inc.
    Formerly CHF Solutions, Inc..
  7. 2023
  8. 💰
    Record revenue of $9 million
    FY2023, the highest of the 8 years on record.

Events of Nuwellis, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$3 M$6 M$10 M$13 M2023202420252026

World rank over time

▲ up 5,162 places since 2022
2022-01-07: #32523#32,52320222022-12-25: #33754#33,75420222023-07-30: #33851#33,85120232024-01-05: #33358#33,35820242026-03-08: #13385#13,38520262026-08-01: #23751#23,75120262026-10-30: #27361#27,3612026

Rank in USA: #5,587 (Jan 2022) · #5,891 (Dec 2022) · #5,700 (Jul 2023) · #4,726 (Jan 2024) · #2,469 (Mar 2026) · #4,143 (Aug 2026) · #4,462 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.3×
Price / book
1.2×
Free cash flow yield
-348.2%
Net margin (TTM)
-152.8%
Operating margin
-134.3%
Return on equity
-525.6%
Liabilities / assets
57.0%
Revenue growth
-5.4%
R&D / revenue
32.8%
Revenue per employee
$218 K
Profit per employee
$-461 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $5M, net income $-17M$5MFY18Fiscal year ending Dec 2019: revenue $6M, net income $-18M$6MFY19Fiscal year ending Dec 2020: revenue $7M, net income $-16M$7MFY20Fiscal year ending Dec 2021: revenue $8M, net income $-20M$8MFY21Fiscal year ending Dec 2022: revenue $9M, net income $-15M$9MFY22Fiscal year ending Dec 2023: revenue $9M, net income $-20M$9MFY23Fiscal year ending Dec 2024: revenue $9M, net income $-11M$9MFY24Fiscal year ending Dec 2025: revenue $8M, net income $-18M$8MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$8M-5.4%$-11M$-18M-211.9%
Dec 2024$9M-1.4%$-11M$-11M-127.7%
Dec 2023$9M+3.7%$-18M$-20M-228.1%
Dec 2022$9M+7.8%$-17M$-15M-170.0%
Dec 2021$8M+6.5%$-20M$-20M-246.8%
Dec 2020$7M+35.0%$-17M$-16M-212.9%
Dec 2019$6M+10.2%$-18M$-18M-328.7%
Dec 2018$5M—$-17M$-17M-340.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-11M$0M$-11M$-25.39—
Dec 2024$-10M$0M$-10M$-353.30—
Dec 2023$-18M$0M$-18M$-360.06—
Dec 2022$-15M$0M$-15M$-83.55—
Dec 2021$-18M$0M$-18M$-285.36—
Dec 2020$-17M$0M$-17M$-10.67—
Dec 2019$-16M$0M$-17M$-278.90—
Dec 2018$-15M$0M$-15M$-42.14—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$9M
Net income, trailing 12 months
$-14M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $2M, net income $-1M$2MDec ’24Three months to Mar 2025: revenue $2M, net income $-3M$2MMar ’25Three months to Jun 2025: revenue $2M, net income $-13M$2MJun ’25Three months to Sep 2025: revenue $2M, net income $0M$2MSep ’25Three months to Dec 2025 (from the annual report): revenue $2M, net income $-2M$2MDec ’25Three months to Mar 2026: revenue $2M, net income $-5M$2MMar ’26Three months to Jun 2026: revenue $2M, net income $-5M$2MJun ’26Three months to Sep 2026: revenue $2M, net income $-2M$2MSep ’26

Latest quarter to Sep 2026: revenue $2M (-0.5% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Nuwellis, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$8 M
Operating income
$-11 M
Net income
$-18 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$6 M
Total liabilities
$3 M
Total equity
$3 M

As of December-2025

Top 11 institutional investors in Nuwellis, Inc.#

As of Sep 30, 2026
11 institutions held 291,487 shares (about 53.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 53.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 11 largest institutional investors in Nuwellis, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Jane Street Group, LLC81,995New15.16%$0 MNov 12, 2026
2Citadel Advisors LLC69,387New12.83%$0 MNov 16, 2026
3Jpmorgan Chase & Co50,846New9.40%$0 MNov 12, 2026
4StoneX Group Inc.38,008New7.03%$0 MNov 3, 2026
5Geode Capital Management, LLC22,760New4.21%$0 MNov 6, 2026
6Virtu Financial LLC20,920New3.87%$0 MNov 17, 2026
7Tower Research Capital LLC (TRC)4,292+4,154 (+3010.14%)0.79%$0 MNov 16, 2026
8UBS Group AG3,118-1,297 (-29.38%)0.58%$0 MNov 10, 2026
9SBI Securities Co., Ltd.92+88 (+2200.00%)0.02%$0 MOct 22, 2026
10Pinnacle Financial Group, Inc.68—0.01%$0 MNov 16, 2026
11Caitong International Asset Management Co., Ltd1New0.00%$0 MOct 29, 2026

Insider trading at Nuwellis, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
25
since
Nuwellis, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed John L. ErbCEO and President, Director, 10% ownerConversion+7,522$0.060$4511.10 MForm 4
filed John L. ErbCEO and President, Director, 10% ownerConversion+1.09 M$0.060$66 K1.09 MForm 4
filed Nestor Jaramillo Jr.President and CEO, DirectorBuy+4,098$4.790$20 K4,098Form 4
filed John L. ErbCEO and President, DirectorBuy+9,523$5.250$50 K11,615Form 4
filed Gregory D. WallerDirectorSell-72$1.030$742Form 4
filed John L. ErbCEO and President, DirectorBuy+23,584$2.120$50 K29,355Form 4
filed Ki Yong Choi10% ownerBuy+30,141$0.480$14 K1.79 MForm 4
filed Ki Yong Choi10% ownerBuy+31,504$0.560$18 K1.76 MForm 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Nuwellis, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
195,586
1 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-35.71 reverse split ; 1-for-41.67 reverse split ; 1-for-34.48 reverse split ; 1-for-100 reverse split ; 1-for-33.33 reverse split ; 1-for-14.01 reverse split ; 1-for-20 reverse split ; 1-for-30.03 reverse split

Trading halts

  • 2026-10-27 16:10 UTC, code LUDP, resumed 16:15 UTC
  • 2026-10-27 15:37 UTC, code LUDP, resumed 15:42 UTC
  • 2026-10-27 15:32 UTC, code LUDP, resumed 15:37 UTC
  • 2026-10-27 15:25 UTC, code LUDP, resumed 15:30 UTC
  • 2026-10-27 15:17 UTC, code LUDP, resumed 15:22 UTC

Fails to deliver

  • : 73,316 shares at $5.78
  • : 30,795 shares at $5.66
  • : 200,366 shares at $5.41
  • : 3,909 shares at $0.32
  • : 7,038 shares at $0.56

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Nuwellis, Inc. scorecard#

Passes 4 of the 18 checks that could be worked out: strongest in valuation (2 of 4), weakest in growth (0 of 6). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median1.2×Price to book 1.2× against Medical Devices's median of 2.5×.
    • ✓Price to sales below its peers' median0.3×Price to sales 0.3× against Medical Devices's median of 2.4×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 6
    • ✗Revenue grew in the newest year-5.4%Revenue down 5.4% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-1.1%-1.1% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-1.1%-1.1% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-25.39 vs -353.30Diluted EPS -25.39 in fiscal 2025 against -353.30 the year before (report's currency).
    • ✗Net income higher than five years earlier-$18 M-$18 M in fiscal 2025 against -$16 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$18 MNet income -$18 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-134.3%-134.3% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-382.9%-382.9% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-134.3%-134.3% in fiscal 2025 against -201.1% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.7×Current ratio 1.71 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-76.04Z-score -76.04 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Nuwellis, Inc.'s statements, beside the median of Medical Devices.

Nuwellis, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-134.3%-8.2%
Net margin-211.9%-10.4%
Return on equity-383.0%-16.8%
Revenue growth, 3 years a year-1.1%10.8%
Revenue growth-5.4%10.4%
Free cash flow margin-131.8%-1.9%

3of 8on the Piotroski tests of financial strength

  • Revenue fell 5.4% against the year before.
  • Net loss of $18 million, the 10th loss-making year in a row.
  • Free cash flow was negative: -$11 million.

Nuwellis, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Nuwellis, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue8.38.78.98.57.97.45.55.03.61.3
Cost of revenue3.13.13.93.83.43.42.73.72.80.7
Gross profit5.15.75.04.84.54.1————
Research and development2.73.25.44.35.03.74.73.11.58.1
Selling, general and administrative1413171819171615108.1
Operating expenses161723222421—221817
Total costs and expenses—————242422——
Operating income−11−11−18−17−20−17−18−17−15−16
Interest expense and finance costs—————————0.5
Other non-operating income (expense)0.0−0.10.20.1−0.0r−0.000.01.40.0
Income before tax−18−11−20−15−20r−16−18−17−13−16
Income tax0.00.00.00.00.00.00.00.00.0−0.1
Net income attributable to shareholders−18−11−20−15−20r−16−18−17−13−16
Earnings per share, basic-25.39-353.30r-360.06r-83.55-285.36r-10.67-278.90r-42.14-525.01r-536.12r
Earnings per share, diluted-25.39-353.30r-360.06r-83.55-285.36r-10.67-278.90r-42.14-525.01r-536.12r
Shares, weighted average (basic)0.70.0r0.1r0.2r0.1r1.6————
Shares, weighted average (diluted)0.70.0r0.1r0.2r0.1r1.60.1r0.40.0r0.0r
Balance sheet
Cash and cash equivalents1.15.13.8188.7r141.35.5161.3
Short-term investments——00.615—————
Receivables1.51.72.01.40.80.90.80.80.50.3
Inventory1.91.72.02.72.83.01.81.71.60.7
Other current assets0.70.30.50.40.30.20.20.20.10.1
Current assets5.28.98.22328194.08.1182.4
Property, plant and equipment0.40.50.71.01.21.21.00.50.60.5
Right-of-use (leased) assets0.30.50.70.91.10.30.40——
Goodwill————————00.2
Other intangible assets0———————04.3
Total assets6.19.99.82530205.68.8187.5
Accounts payable2.21.62.42.21.41.11.51.10.92.0r
Current liabilities3.02.63.24.73.33.63.42.82.13.3
Lease liabilities (non-current)0.10.30.50.81.00.10.30——
Total liabilities3.53.36.6124.53.73.62.82.25.2
Retained earnings−316−299−288−267−253r−233−218−199−182−169
Shareholders' equity2.66.53.01226162.05.9161.8
Total liabilities and equity6.19.99.82530205.68.8187.5
Shares outstanding0.0r0.1r0.2r0.50.1r2.70.2r0.50.3r0.0r
Cash-flow statement
Depreciation and amortization0.20.30.40.40.50.40.20.20.80.7
Share-based compensation0.10.50.70.91.31.31.52.10.50.9
Cash from operating activities−11−9.6−18−15−18r−17−16−15−12−16
Capital expenditure−0.1−0.1−0.1−0.1−0.2−0.3−0.5−0.2−0.3−0.1
Intangible assets bought—0−0.10——————
Acquisitions, net of cash acquired————————0−4.0
Cash from investing activities−0.1−0.10.315−16r−0.3−0.5−0.2−0.3−4.1
Debt repaid————————0−8.0
Shares issued4.02.4————————
Cash from financing activities6.9113.79.42830134.626−1.4
Exchange-rate effect on cash0.1−0.0−0.0−0.0−0.0—————
Change in cash−3.91.3−149.0−5.7r13−4.2−1014−22
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Nuwellis, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Business segments

  • Fluid Overload$8 M100%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Events at Nuwellis, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 7 · Material agreement 3 · Unregistered share sale 2 · Shareholder rights changed 3 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 6

Nuwellis, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Shareholder vote8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Directors and officers8-K/A
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Directors and officersMaterial agreementUnregistered share saleShareholder rights changed8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of Nuwellis, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2024$4 MPrivate placement after listing$2 to $10 million9optionsSEC
May 2020$2 MPrivate placement after listingUnder $2 million4equity, optionsSEC
Apr 2020$2 MPrivate placement after listing$2 to $10 million4equity, optionsSEC
Mar 2020$1 MPrivate placement after listingUnder $2 million4equity, optionsSEC
Nov 2019$1 MPrivate placement after listingUnder $2 million3equity, optionsSEC
Oct 2016$4 MPrivate placement after listing$2 to $10 million2equity, optionsSEC
Jul 2016$3 MPrivate placement after listing$2 to $10 million2optionsSEC
Jan 2013$2 MNo. 4Under $2 million1equitySEC
Feb 2012$2 MNo. 3$2 to $10 million4equity, optionsSEC
Jul 2011$5 MNo. 2$2 to $10 million9equity, optionsSEC
Nov 2010$4 MNo. 1$2 to $10 million7equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Nuwellis, Inc.#

$0 spent on lobbying the US Congress and federal agencies in 2021, most often on health issues and medicare/medicaid.

Lobbying, 2021
$0
#1,452 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2021
2026 so far
—
  • Health Issues2 reports
  • Medicare/Medicaid2 reports

Lobbying firms hired in 2021

Liberty Partners Group, LLC

Nuwellis, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2021$0—2
2020$180 K—3

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “CHF Solutions, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Nuwellis, Inc.#

1 labor condition applications certified in fiscal 2024 for 1 positions, at a median wage of $120 K a year.

Certified, FY2024
1
#2,010 among companies on value.today
Worker positions
1
Median wage offered
$120 K
a year, full-time
Applications filed
1
Nuwellis, Inc.: most frequent H-1B job titles in fiscal 2024
Job titlePositionsMedian wage offered
Principal Design Assurance Quality EngineerMechanical Engineers1$120 K

Where: Eden Prairie, MN 1

Nuwellis, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202411$120 K1
FY202111$90 K1
FY202011$80 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Nuwellis, Inc. and CHF Solutions, Inc.

How Nuwellis, Inc. compares in Medical Devices

  • Market cap$3 M · higher than 1% of 142
  • Revenue$8 M · higher than 14% of 155
  • Net margin-152.8% · higher than 10% of 144
  • Revenue growth-5.4% · higher than 12% of 104
  • Price / sales0.3× · lower than 98% of 96
  • Price / book1.2× · lower than 84% of 99

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Nuwellis, Inc.🇺🇸$3 M—-152.8%-5.4%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Nuwellis, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Nuwellis, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Nuwellis, Inc.? Suggest a correction